JPRN-jRCT2080221725未知3 期
A Phase III, Randomized, Placebo and Active-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of the Addition of Metformin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Sitagliptin Monotherapy
MSD K.K. and ONO PHARMACEUTICAL CO.,LTD.0 个研究点目标入组 337 人开始时间: 2012年2月28日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 337
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •1.Type 2 Diabetes Mellitus
- •2.Currently being treated with diet/exercise and on stable dose of sitagliptin for >=4 weeks, on any additional oral hypoglycemic agent (AHA) in the prior 8 weeks, and HbA1c >=6.0% and =<9.0%; or, currently being treated with diet/exercise and on stable dose of sitagliptin for >=10 weeks, not on any additional oral AHA in the prior 8 weeks, and HbA1c >=6.5% and <10.0%
排除标准
- •1.Type 1 diabetes mellitus, secondary diabetes mellitus, or gestational diabetes mellitus
研究者
相似试验
进行中（未招募）
不适用
Phase 3, Adolescent Large Scale Safety StudyBacterial MeningitisMedDRA version: 14.0Level: LLTClassification code 10004049Term: Bacterial meningitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-015198-11-DKPfizer Inc, 235 East 42nd Street, New York, NY 100177,500
已完成
不适用
urasidone HCl A Phase 3 Study of Patients With Acute SchizophreniaPER-052-08DAINIPPON SUMITOMO PHARMA AMERICA, INC,
进行中（未招募）
不适用
A Phase 3 Randomized, Placebo- and Active Comparator-Controlled Clinical Trial toStudy the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely PsychoticPatients with SchizophreniaSchizophreniaEUCTR2007-003820-40-LTDainippon Sumitomo Pharma America, Inc.490
进行中（未招募）
不适用
Phase 3, Adolescent Large Scale Safety StudyBacterial MeningitisMedDRA version: 14.1Level: LLTClassification code 10004049Term: Bacterial meningitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-015198-11-ESPfizer Inc, 235 East 42nd Street, New York, NY 100177,500
进行中（未招募）
1 期
A Study of Ramucirumab plus Docetaxel in Participants with Urothelial Cancer.ocally advanced or unresectable or metastatic urothelial carcinoma whohave had disease progression on or after one prior first-line platinumbasedchemotherapyMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2014-003655-66-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER524